Renin-Angiotensin System Inhibition Following Transcatheter Aortic Valve Replacement

Journal of the American College of Cardiology

Volumn 74, Issue 5, 2019, Pages 631-641

  Rodriguez Gabella, Tania ^a   Catalá, Pablo ^a   Muñoz García, Antonio J ^b   Nombela Franco, Luis ^c   Del Valle, Raquel ^d   Gutiérrez, Enrique ^e   Regueiro, Ander ^f   Jimenez Diaz, Victor A ^g   Ribeiro, Henrique B ^h   Rivero, Fernando ⁱ   Fernandez Diaz, Jose Antonio ^j   Pibarot, Philippe ^k   Alonso Briales, Juan H ^b   Tirado Conte, Gabriela ^c   Moris, César ^d   Diez Del Hoyo, Felipe ^e   Jiménez Britez, Gustavo ^g   Zaderenko, Nicolas ^h   Alfonso, Fernando ⁱ   Gómez, Itziar ^a   Carrasco Moraleja, Manuel ^a   Rodés Cabau, Josep ^k   San Román Calvar, J Alberto ^a   Amat Santos, Ignacio J ^a   more..

^a HOSPITAL CLÍNICO UNIVERSITARIO DE VALLADOLID   (Spain)

^b HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^c HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^d HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^f HOSPITAL CLÍNIC   (Spain)

^g CIBERCV   (Spain)

^h UNIVERSITY OF SÃO PAULO   (Brazil)

ⁱ HOSPITAL UNIVERSITARIO DE LA PRINCESA   (Spain)

^j HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^k LAVAL UNIVERSITY   (Canada)

more..

Author keywords

fibrosis; hypertrophy; RAS inhibitors; TAVR

Indexed keywords

EPLERENONE; SACUBITRIL; SPIRONOLACTONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; AORTIC STENOSIS; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; FEMALE; FOLLOW UP; HEART INFARCTION; HEART LEFT VENTRICLE VOLUME; HEART VENTRICLE REMODELING; HEART VENTRICLE VOLUME; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; HYPERTROPHY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; ODDS RATIO; POPULATION RESEARCH; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RETROSPECTIVE STUDY; SCORING SYSTEM; SURGICAL RISK; TRANSCATHETER AORTIC VALVE IMPLANTATION; TREATMENT OUTCOME; VERY ELDERLY; ADVERSE EVENT; AORTIC VALVE; AORTIC VALVE STENOSIS; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DRUG EFFECT; ECHOCARDIOGRAPHY; ETIOLOGY; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE; PATHOPHYSIOLOGY; PHYSIOLOGY; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREVENTION AND CONTROL; RISK FACTOR; SURGERY;

AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; AORTIC VALVE; AORTIC VALVE STENOSIS; ECHOCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HEART VENTRICLES; HUMANS; MALE; POSTOPERATIVE COMPLICATIONS; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDIES; RISK FACTORS; TRANSCATHETER AORTIC VALVE REPLACEMENT; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 85069592429     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2019.05.055     Document Type: Article

References (27)

1. Leon, M.B., Smith, C.R., Mack, M., et al. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363 (2010), 1597–1607.
2. Smith, C.R., Leon, M.B., Mack, M., et al. Transcatheter versus surgical aortic-vale replacement in high-risk patients. N Engl J Med 364 (2011), 2187–2198.
3. Arnold, S.V., Reynolds, M.R., Wang, K., et al. Health status after transcatheter or surgical aortic valve replacement in patients with severe aortic stenosis at increased surgical risk: results from the CoreValve US pivotal trial. J Am Coll Cardiol Intv 8 (2015), 1207–1217.
4. Reardon, M.J., Van Mieghem, N.M., Popma, J.J., et al., for the SURTAVI Investigators. Surgical or transcatheter aortic-valve replacement in intermediate-risk patients. N Engl J Med 376 (2017), 1321–1331.
5. Leon, M.B., Smith, C.R., Mack, M.J., et al., for the PARTNER 2 Investigators. Transcatheter or surgical aortic-valve replacement in intermediate-risk patients. N Engl J Med 374 (2016), 1609–1620.
6. Everett, R.J., Tastet, L., Clavel, M.A., et al. Progression of hypertrophy and myocardial fibrosis in aortic stenosis: a multicenter cardiac magnetic resonance study. Circ Cardiovasc Imaging, 11, 2018, e007451.
7. Yiu, K.H., Ng, W.S., Chan, D., et al. Improved prognosis following renin-angiotensin-aldosterone system blockade in patients undergoing concomitant aortic and mitral valve replacement. Int J Cardiol 177 (2014), 680–682.
8. Magne, J., Guinot, B., Le Guyader, A., et al. Relation between renin-angiotensin system blockers and survival following isolated aortic valve replacement for aortic stenosis. Am J Cardiol 121 (2018), 455–460.
9. Musa, T.A., Treibel, T.A., Vassiliou, V.S., et al. Myocardial scar and mortality in severe aortic stenosis. Circulation 138 (2018), 1935–1947.
10. Hale, T.M., Persistent phenotypic shift in cardiac fibroblast: impact of transient renin angiotensin system inhibition. J Mol Cell Cardiol 93 (2016), 125–132.
11. Kappetein, A.P., Head, S.J., Généreux, P., et al. Update standardized endpoint definition for transcatheter aortic valve implantation: the Valve Academic Research Consortium-2 consensus document. J Thorac Cardiovasc Surg 145 (2013), 6–23.
12. Zoghbi, W.A., Chambers, J.B., Dumesnil, J.G., et al. Recommendations for evaluation of prosthetic valves with echocardiography and Doppler ultrasound: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Task Force on Prosthetic Valves. J Am Soc Echocardiogr 22 (2009), 975–1014.
13. Haukoos, J.S., Lewis, R.J., The propensity score. JAMA 314 (2015), 1637–1638.
14. Bing, R., Cavalcante, J.L., Everett, R.J., et al. Imaging and impact of myocardial fibrosis in aortic stenosis. J Am Coll Cardiol Img 12 (2019), 283–296.
15. Treibel, T.A., Kozor, R., Shofield, R., et al. Reverse myocardial remodelling following valve replacement in patients with aortic stenosis. J Am Coll Cardiol 71 (2018), 860–871.
16. Hermans, K.C., Daskalapoulos, E.P., Blankensteijn, W.M., The Janus face of myofibroblasts in the remodeling heart. J Mol Cell Cardiol 91 (2016), 35–41.
17. Camelliti, P., Borg, T.K., Kohl, P., Structural and functional characterisation of cardiac fibroblasts. Cardiovasc Res 65 (2005), 40–51.
18. Inohara, T., Manandhar, P., Kosinski, A.S., et al. Association of renin-angiotensin inhibitor treatment with mortality and heart failure readmission in patients with transcatheter aortic valve replacement. JAMA 320 (2018), 2231–2241.
19. Ochiai, T., Saito, S., Yamanaka, F., et al. Renin-angiotensin system blockade therapy after transcatheter aortic valve implantation. Heart 104 (2018), 644–651.
20. Peng, H., Carretero, O.A., Vuljaj, N., et al. Angiotensin-converting enzyme inhibitors: a new mechanism of action. Circulation 112 (2005), 2436–2445.
21. Leuschner, F., Panizzi, P., Chico-Calero, I., et al. Angiotensin-converting enzyme inhibition prevents the release of monocytes from their splenic reservoir in mice with myocardial infarction. Circ Res 26 (2010), 1364–1373.
22. Baumann, M., Janssen, B.J., Hermans, J.J., et al. Transient AT1 receptor-inhibition in prehypertensive spontaneously hypertensive rats results in maintained cardiac protection until advanced age. J Hypertens 25 (2007), 207–215.
23. Peng, F., Lin, J., Lin, L., Tang, H., Transient prehypertensive treatment in spontaneously hypertensive rats: a comparison of losartan and amlodipine regarding long-term blood pressure, cardiac and renal protection. Int J Mol Med 30 (2012), 1376–1386.
24. Ciulla, M.M., Paliotti, R., Esposito, A., et al. Different effects of antihypertensive therapies based on losartan or atenolol on ultrasound and biochemical markers of myocardial fibrosis: results of a randomized trial. Circulation 110 (2004), 552–557.
25. Díez, J., Querejeta, R., López, B., et al. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 105 (2002), 2512–2517.
26. Amat-Santos, I.J., Catalá, P., Diez Del Hoyo, F., et al. Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study. BMJ Open, 8, 2018, e020255.
27. Vora, A.N., Matsuoka, R., Harrison, J.K., et al. Incidence, management, and associated clinical outcomes of new-onset atrial fibrillation following transcatheter aortic valve replacement: an analysis from the STS/ACC TVR Registry. J Am Coll Cardiol Intv 11 (2018), 1746–1756.